Focused On-demand Library for Immunoglobulin heavy constant alpha 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P01877

UPID:

IGHA2_HUMAN

Alternative names:

Ig alpha-2 chain C region; Ig alpha-2 chain C region BUT; Ig alpha-2 chain C region LAN

Alternative UPACC:

P01877; A0A075B6N7; A0A286YEY5

Background:

Immunoglobulin heavy constant alpha 2 (Ig alpha-2 chain C region) plays a pivotal role in humoral immunity. It is a part of immunoglobulins, or antibodies, which are produced by B lymphocytes. These antibodies can be either membrane-bound or secreted and are essential for the recognition and elimination of antigens. The antigen binding site of each immunoglobulin is highly specific, allowing for the precise targeting of antigens. This specificity is achieved through V-(D)-J rearrangement and somatic hypermutations.

Therapeutic significance:

Understanding the role of Immunoglobulin heavy constant alpha 2 could open doors to potential therapeutic strategies.